NR 565 | Midterm Practice Examination Page 1
, NR 565 MIDTERM EXAM
Advanced Pharmacology Fundamentals
Chamberlain University
100-Question Original Practice Examination
2026/2027 Edition
1. An oral medicine has extensive first-pass hepatic metabolism. Compared with an equal intravenous dose, which result
is most likely?
A) Elimination of hepatic exposure
B) An unchanged fraction reaching circulation
C) Higher absolute bioavailability
D) Lower systemic bioavailability
Correct Answer: Lower systemic bioavailability
Rationale: First-pass extraction removes some absorbed drug before it reaches systemic circulation. Intravenous dosing bypasses
intestinal absorption and the initial portal passage. Oral dose adjustments may therefore be necessary, but the effect depends on
the specific drug and liver function.
2. A medicine is 98% albumin-bound. Severe hypoalbuminemia is most likely to cause which immediate change?
A) A complete loss of drug effect
B) A higher free fraction of drug
C) A fixed increase in renal clearance
D) A higher measured albumin concentration
Correct Answer: A higher free fraction of drug
Rationale: Only unbound drug can readily distribute to receptors and undergo filtration. Reduced binding may transiently increase
active free concentrations, although distribution and clearance can subsequently change. Total plasma concentration alone may
be misleading for highly bound agents.
3. An older adult begins a renally eliminated drug while estimated kidney function is substantially reduced. What is the
best prescribing response?
A) Use liver enzymes alone to select the dose
B) Adjust the regimen using renal function and drug guidance
C) Double the maintenance dose automatically
NR 565 | Midterm Practice Examination Page 2
, D) Assume age has no effect on exposure
Correct Answer: Adjust the regimen using renal function and drug guidance
Rationale: Reduced renal clearance can prolong exposure and raise toxicity risk. The dosing interval, amount, or both may need
adjustment according to validated guidance. Age alone is an imperfect proxy, so measured or estimated kidney function and
clinical response matter.
4. A drug's elimination half-life is 8 hours. Approximately how much remains 24 hours after a single dose, assuming first-
order elimination?
A) 25%
B) 12.5%
C) 50%
D) 33%
Correct Answer: 12.5%
Rationale: Twenty-four hours represents three half-lives. The amount remaining is one-half cubed, or one-eighth of the initial
amount. This approximation assumes first-order kinetics and does not account for additional doses or active metabolites.
5. A patient has taken a fixed dose of a drug for one day and asks why concentrations have not stabilized. What best
explains steady state?
A) It usually takes roughly four to five elimination half-lives
B) It depends only on tablet color
C) It requires complete receptor saturation
D) It always occurs after exactly one dose
Correct Answer: It usually takes roughly four to five elimination half-lives
Rationale: With repeated dosing, drug input and elimination gradually approach balance. For many first-order drugs,
concentrations approach steady state after about four to five half-lives. Dose size changes the concentration reached, not the
approximate time required.
6. A medication has a narrow therapeutic index. Which management plan best reduces preventable harm?
A) Use indicated serum monitoring and review interactions
B) Avoid documenting concurrent medications
C) Assume a normal pulse excludes toxicity
D) Increase doses until any adverse effect occurs
Correct Answer: Use indicated serum monitoring and review interactions
NR 565 | Midterm Practice Examination Page 3
, Rationale: The therapeutic and toxic concentrations are close for narrow-index drugs. When applicable, measured concentrations,
renal function, clinical effects, and interaction checks guide safe individualization. No single normal vital sign reliably rules out
medication toxicity.
7. A medication's potency increases while its maximal efficacy remains unchanged.
How would its dose-response curve usually change?
A) Show lower receptor affinity by definition
B) Become flat at all doses
C) Shift right with greater maximal response
D) Shift left without a higher maximal response
Correct Answer: Shift left without a higher maximal response
Rationale: A more potent drug produces a given response at a lower dose, often represented by a leftward shift. Efficacy refers to
the maximum attainable response. Potency does not by itself establish superior clinical outcomes or safety.
8. Two agonists act at the same receptor; one produces a lower maximum response despite full receptor occupancy.
That drug is best described as what?
A) A partial agonist
B) A noncompetitive enzyme inhibitor
C) A full agonist with greater efficacy
D) An irreversible antagonist
Correct Answer: A partial agonist
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist at the same receptor. In the presence of a full agonist, it
can also reduce overall receptor activation by competing for binding sites.
9. A reversible competitive antagonist is added to an agonist. Which change is expected in a typical dose-response
experiment?
A) The receptor is permanently destroyed
B) Drug metabolism always stops
C) More agonist is needed to achieve the same effect
D) The agonist's maximum effect must become zero
Correct Answer: More agonist is needed to achieve the same effect
Rationale: A surmountable competitive antagonist occupies the agonist binding site. Raising agonist concentration can overcome
the blockade, producing a rightward shift with a potentially unchanged maximum. Clinical behavior may be more complex when
toxicity limits dose escalation.
NR 565 | Midterm Practice Examination Page 4
, NR 565 MIDTERM EXAM
Advanced Pharmacology Fundamentals
Chamberlain University
100-Question Original Practice Examination
2026/2027 Edition
1. An oral medicine has extensive first-pass hepatic metabolism. Compared with an equal intravenous dose, which result
is most likely?
A) Elimination of hepatic exposure
B) An unchanged fraction reaching circulation
C) Higher absolute bioavailability
D) Lower systemic bioavailability
Correct Answer: Lower systemic bioavailability
Rationale: First-pass extraction removes some absorbed drug before it reaches systemic circulation. Intravenous dosing bypasses
intestinal absorption and the initial portal passage. Oral dose adjustments may therefore be necessary, but the effect depends on
the specific drug and liver function.
2. A medicine is 98% albumin-bound. Severe hypoalbuminemia is most likely to cause which immediate change?
A) A complete loss of drug effect
B) A higher free fraction of drug
C) A fixed increase in renal clearance
D) A higher measured albumin concentration
Correct Answer: A higher free fraction of drug
Rationale: Only unbound drug can readily distribute to receptors and undergo filtration. Reduced binding may transiently increase
active free concentrations, although distribution and clearance can subsequently change. Total plasma concentration alone may
be misleading for highly bound agents.
3. An older adult begins a renally eliminated drug while estimated kidney function is substantially reduced. What is the
best prescribing response?
A) Use liver enzymes alone to select the dose
B) Adjust the regimen using renal function and drug guidance
C) Double the maintenance dose automatically
NR 565 | Midterm Practice Examination Page 2
, D) Assume age has no effect on exposure
Correct Answer: Adjust the regimen using renal function and drug guidance
Rationale: Reduced renal clearance can prolong exposure and raise toxicity risk. The dosing interval, amount, or both may need
adjustment according to validated guidance. Age alone is an imperfect proxy, so measured or estimated kidney function and
clinical response matter.
4. A drug's elimination half-life is 8 hours. Approximately how much remains 24 hours after a single dose, assuming first-
order elimination?
A) 25%
B) 12.5%
C) 50%
D) 33%
Correct Answer: 12.5%
Rationale: Twenty-four hours represents three half-lives. The amount remaining is one-half cubed, or one-eighth of the initial
amount. This approximation assumes first-order kinetics and does not account for additional doses or active metabolites.
5. A patient has taken a fixed dose of a drug for one day and asks why concentrations have not stabilized. What best
explains steady state?
A) It usually takes roughly four to five elimination half-lives
B) It depends only on tablet color
C) It requires complete receptor saturation
D) It always occurs after exactly one dose
Correct Answer: It usually takes roughly four to five elimination half-lives
Rationale: With repeated dosing, drug input and elimination gradually approach balance. For many first-order drugs,
concentrations approach steady state after about four to five half-lives. Dose size changes the concentration reached, not the
approximate time required.
6. A medication has a narrow therapeutic index. Which management plan best reduces preventable harm?
A) Use indicated serum monitoring and review interactions
B) Avoid documenting concurrent medications
C) Assume a normal pulse excludes toxicity
D) Increase doses until any adverse effect occurs
Correct Answer: Use indicated serum monitoring and review interactions
NR 565 | Midterm Practice Examination Page 3
, Rationale: The therapeutic and toxic concentrations are close for narrow-index drugs. When applicable, measured concentrations,
renal function, clinical effects, and interaction checks guide safe individualization. No single normal vital sign reliably rules out
medication toxicity.
7. A medication's potency increases while its maximal efficacy remains unchanged.
How would its dose-response curve usually change?
A) Show lower receptor affinity by definition
B) Become flat at all doses
C) Shift right with greater maximal response
D) Shift left without a higher maximal response
Correct Answer: Shift left without a higher maximal response
Rationale: A more potent drug produces a given response at a lower dose, often represented by a leftward shift. Efficacy refers to
the maximum attainable response. Potency does not by itself establish superior clinical outcomes or safety.
8. Two agonists act at the same receptor; one produces a lower maximum response despite full receptor occupancy.
That drug is best described as what?
A) A partial agonist
B) A noncompetitive enzyme inhibitor
C) A full agonist with greater efficacy
D) An irreversible antagonist
Correct Answer: A partial agonist
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist at the same receptor. In the presence of a full agonist, it
can also reduce overall receptor activation by competing for binding sites.
9. A reversible competitive antagonist is added to an agonist. Which change is expected in a typical dose-response
experiment?
A) The receptor is permanently destroyed
B) Drug metabolism always stops
C) More agonist is needed to achieve the same effect
D) The agonist's maximum effect must become zero
Correct Answer: More agonist is needed to achieve the same effect
Rationale: A surmountable competitive antagonist occupies the agonist binding site. Raising agonist concentration can overcome
the blockade, producing a rightward shift with a potentially unchanged maximum. Clinical behavior may be more complex when
toxicity limits dose escalation.
NR 565 | Midterm Practice Examination Page 4
